Skip to content

Price / book at other companies

Evolent Health, Inc. logo
Evolent Health, Inc.EVH
0.6×-0.5×
Immunome logo
ImmunomeIMNM
4.2×+2.3×
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
3.1×-1.2×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
4.1×+2.3×
Exelixis logo
ExelixisEXEL
5.8×+1.0×

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Calculated from The Oncology Institute, Inc.’s reported figures.

Based on the most recent quarter.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s price / book?
The Oncology Institute, Inc. (TOI) reported price / book of 19.7× in Q1 2025.
How has The Oncology Institute, Inc.'s price / book changed year-over-year?
The Oncology Institute, Inc.'s price / book increased by 594.9% year-over-year, from 2.8× to 19.7×.
What is the long-term trend for The Oncology Institute, Inc.'s price / book?
Over 4 years (2020 to 2024), The Oncology Institute, Inc.'s price / book has grown at a -28.8% compound annual growth rate (CAGR), from 25.4× to 6.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.